News Releases


2017 | 2016 | 2015 | Archive
Keyword Search
 
DateTitle 
12/15/15ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Dec. 15, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced Julian C. Baker has joined its Board of Directors. “After more than 20 years as a professional investor, Julian has extensive experience in financing and building companies in t... 
Printer Friendly Version
11/30/15ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development
SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment of Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development. With a background in clinical and academic psychiatry, ... 
Printer Friendly Version
11/30/15ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Edmund P. Harrigan, M.D., has joined its Board of Directors. Dr. Harrigan is a board-certified neurologist with 25 years of executive leadership experience in the pharmaceutical ... 
Printer Friendly Version
11/05/15ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its unaudited financial results for the third quarter ended September 30, 2015. ACADIA reported a net loss of $38.9 million, or $0.39 per common share, for the third quart... 
Printer Friendly Version
11/04/15ACADIA Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference on November 10, 2015
SAN DIEGO--(BUSINESS WIRE)--Nov. 4, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at the 24th Annual Credit Suisse Healthcare Conference on Tuesday, November 10, 2015, at 11:30 a.m. Mountain Standard Time in Scottsdale, Arizona. A l... 
Printer Friendly Version
11/02/15ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis
PDUFA Date Set for May 1, 2016 SAN DIEGO--(BUSINESS WIRE)--Nov. 2, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that the New Drug Application (NDA) for NUPLAZID™ (pimavanserin) has been accepted for review by the U.S. Food and Drug Administration (FDA) and ... 
Printer Friendly Version
10/29/15ACADIA Pharmaceuticals to Announce Third Quarter Financial Results on November 5, 2015
ACADIA to Host Conference Call and Webcast on Thursday, November 5, 2015, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its unaudited financial results for the thir... 
Printer Friendly Version
09/22/15ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
SAN DIEGO--(BUSINESS WIRE)--Sep. 22, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at the Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29, 2015, at 10:00 a.m. Eastern Time in New York City. A live webcast of A... 
Printer Friendly Version
09/03/15ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer
SAN DIEGO--(BUSINESS WIRE)--Sep. 3, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that its Board of Directors has appointed Steve Davis as President and Chief Executive Officer. Mr. Davis has been serving as ACADIA’s Interim Chief Executive Officer since March 2015. M... 
Printer Friendly Version
09/03/15ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--Sep. 3, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with ... 
Printer Friendly Version
08/06/15ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Aug. 6, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the second quarter ended June 30, 2015. ACADIA reported a net loss of $39.4 million, or $0.39 per common share, ... 
Printer Friendly Version
08/06/15ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association
SAN DIEGO--(BUSINESS WIRE)--Aug. 6, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced the publication of new data from its ongoing open-label safety extension study, the -015 Study, with NUPLAZID™ in patients with Parkinson’s disease psychosis (... 
Printer Friendly Version
08/05/15ACADIA Pharmaceuticals Announces Senior Management Appointments in Manufacturing, Quality, Compliance, Access and Reimbursement and Business Development
SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced the following senior management appointments: James A. Nash, Senior Vice President, Technology Development and Operations ... 
Printer Friendly Version
07/30/15ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015
ACADIA to Host Conference Call and Webcast on Thursday, August 6, 2015, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Jul. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financi... 
Printer Friendly Version
06/17/15ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
SAN DIEGO--(BUSINESS WIRE)--Jun. 17, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015, at 11:00 a.m. Eastern Time in New York City. A live webcast of ACADIA’s presentation w... 
Printer Friendly Version
06/16/15ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
Data from Integrated Analysis of Two Phase III Studies Show Robust and Consistent Efficacy of NUPLAZID Across a Wide Array of Study Measures Data from Two Open-Label Studies Demonstrate Attractive Safety and Tolerability Profile and Potential for Long-Term Effectiveness of NUPLAZID in Parkinson’s Disease Psychosis SAN DIEGO--(BUSINESS WIRE)--Jun. 16, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company ... 
Printer Friendly Version
05/26/15ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015
SAN DIEGO--(BUSINESS WIRE)--May 26, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2015 Healthcare Conference on Tuesday, June 2, 2015, at 1:30 p.m. Eastern Time in New York City. A live webcast of ACADIA’s presentation will be a... 
Printer Friendly Version
05/07/15ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 7, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2015. ACADIA reported a net loss of $40.4 million, or $0.40 per common share, ... 
Printer Friendly Version
05/06/15ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015
SAN DIEGO--(BUSINESS WIRE)--May 6, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015, at 4:20 p.m. Pacific Time in Las Vegas. A live webcast of ACADIA’s pres... 
Printer Friendly Version
04/30/15ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015
ACADIA to Host Conference Call and Webcast on Thursday, May 7, 2015, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Apr. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results ... 
Printer Friendly Version
04/07/15ACADIA Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference on April 14, 2015
SAN DIEGO--(BUSINESS WIRE)--Apr. 7, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015, at 9:20 a.m. Eastern Time in New York City. A live webcast of ACADIA’s presentation wi... 
Printer Friendly Version
03/26/15ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Mar. 26, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Daniel Soland has joined its Board of Directors. Mr. Soland is a seasoned pharmaceutical executive with over 30 years of experience in the biopharmaceuti... 
Printer Friendly Version
03/11/15ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer
Steve Davis Appointed Interim Chief Executive Officer SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of the Boa... 
Printer Friendly Version
03/11/15ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZID™ NDA Submission
Conference Call Scheduled for Today, March 11, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today provided an update on the planned timing of its NUPLAZIDTM (pimavanserin) New Drug A... 
Printer Friendly Version
02/26/15ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014
SAN DIEGO--(BUSINESS WIRE)--Feb. 26, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2014. ACADIA reported a net loss of $28.4 million, or $0.28 per common share,... 
Printer Friendly Version
02/24/15ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Feb. 24, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015, at 10:40 a.m. Eastern Time in Bost... 
Printer Friendly Version
02/19/15ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
ACADIA to Host Conference Call and Webcast on Thursday, February 26, 2015, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 19, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its financial resu... 
Printer Friendly Version
01/06/15ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015, at 11:30 a.m. Pacific Time in San Francisco. A live webcast of ACADIA’s presenta... 
Printer Friendly Version